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Extensively drug-
resistant tuberculosis in 
South Africa
Keertan Dheda and colleagues 
(May 22, p 1798)
1 report extremely 
poor treatment outcomes for patients 
with extensively drug-resistant (XDR) 
tuberculosis in South Africa and 
conclude that prevention of XDR 
tuberculosis through strengthening 
of tuberculosis pro  grammes overall 
should be prioritised.
Most patients diagnosed with XDR 
tuberculosis in this cohort (72%) 
had previously been diagnosed with 
multidrug-resistant  (MDR) tuberculosis. 
Presumably, these patients received 
treatment for MDR tuberculosis 
before diagnosis of XDR tuberculosis. 
The standard treatment available for 
MDR tuberculosis at the time of the 
study, as described, is a relatively weak 
regimen likely to lead to ampliﬁ  cation 
of resistance—patients with strains 
of  Mycobacterium tuberculosis already 
resistant to one of the second-line 
injectable agents or a ﬂ  uoroquinolone 
are likely to develop XDR tuberculosis 
even with good treatment adherence.
Thus, another important strategy 
to prevent XDR tuberculosis is to 
ensure adequate treatment of MDR 
tuberculosis. A regimen for all cases 
of MDR tuberculosis  that contains 
moxi ﬂ  oxacin and at least three other 
drugs that are likely to be eﬀ  ective 
will no doubt substantially reduce the 
creation of XDR tuberculosis  during 
treatment. Contrary to what some 
suggest,
2 moxiﬂ  oxacin is well tolerated 
and unlikely to contribute to additional 
adverse events.
3 Such a regimen needs 
to balance tolerability against eﬃ   cacy, 
both in terms of cure and prevention of 
further resistance.
The contribution of previous treat-
ment of MDR tuberculosis to poor 
outcomes in this study is unclear, 
but might well explain the disparity 
between this study and the relatively 
good outcomes reported from Peru 
in patients treated with more robust 
second-line regimens.
4 Given extensive 
previous treatment in the South 
African cohort, outcomes might not 
be generalisable to patients initially 
diagnosed with XDR tuberculosis and 
treated appropriately.
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Keertan Dheda and colleagues
1 found 
poor treatment outcomes and high 
mortality in patients with extensively 
drug-resistant (XDR) tuberculosis in 
South Africa. Only 19% of patients 
showed culture conversion and I am 
very surprised to see that drugs such 
as amikacin, kanamycin, and oﬂ  oxacin 
were used in the treatment regimen 
despite the fact that all the patients 
with XDR tuberculosis were resistant 
to them. Oﬂ  oxacin was used in 18% 
of patients and thus might have 
contributed to poor culture conversion.
The high mortality seen in this study 
is a matter of great concern. Since the 
number of deaths was not signiﬁ  cantly 
diﬀ  erent in patients with or without 
HIV infection, Dheda and colleagues 
should have looked for other important 
comorbidities such as diabetes mellitus 
in patients with XDR tuberculosis. 
Diabetes has been shown to be the 
most common comorbidity in patients 
with culture-conﬁ  rmed  tuberculosis.
2 
It is also well known that diabetes has 
a negative eﬀ  ect on the outcome of 
tuberculosis treatment. Diabetes is 
associated with longer time to culture 
conversion, treatment failure, and high 
mortality rate in patients undergoing 
tuberculosis treatment.
3–5 
In a setting with a high degree of HIV 
co-infection, careful considerations 
must be given to supervised treatment 
of susceptible and multidrug-resistant 
tuberculosis with the appropriate 
regimens along with management of 
important comorbidities to prevent 
the emergence of XDR tuberculosis. 
More such studies are required to 
provide greater insight into the 
menace of XDR tuberculosis.
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Authors’ reply
We agree with Helen Cox and 
colleagues that, given the poor treat-
ment-related outcomes for extensively 
drug-resistant (XDR) tuber  culosis, and 
the likelihood of multidrug-resistant 
(MDR) tuberculosis progressing to 
XDR tuberculosis, hitting hard with 
the most potent available drug 
regimen at ﬁ   rst contact with MDR 
tuberculosis is crucial for prevention 
of XDR tuberculosis.
1 Thus, it would be 
rational to use third-generation ﬂ  uoro-
quinolones to treat MDR tuberculosis. 
A
P
The printed 
journal 
includes an 
image merely 
for illustration